Resorbable Magnesium Scaffolds Registry

November 18, 2025 updated by: Biotronik AG

RMS (Resorbable Magnesium Scaffolds) Registry

The registry follows the ESC/EACTS guideline and further investigates the clinical performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (IFU).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1106

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Australia
      • Cairns, Australia, 4870
        • Completed
        • Cairns Hospital
  • Germany
      • Bad Segeberg, Germany, 23795
        • Recruiting
        • Heart Center Segeberger Kliniken
        • Contact:
          • Holger Nef, MD
        • Contact:
          • Ralph Toelg, MD
      • Buchholz, Germany, 21244
        • Completed
        • Krankenhaus Buchholz
      • Dortmund, Germany, 44309
        • Completed
        • Klinikum Westfalen, Knappschaft KH
      • Herford, Germany, 32049
        • Completed
        • Klinikum Herford
      • Kempten, Germany
        • Completed
        • Herz-und Gefäßzentrum Oberallgäu-Kempten
  • Italy
    • Lombardy
      • Milan, Lombardy, Italy, 20138
        • Recruiting
        • Centro Cardiologico Monzino
        • Contact:
          • Stefano Galli, MD
  • Latvia
      • Daugavpils, Latvia, LV-5417
        • Completed
        • Daugavpils Regional Hospital
  • Poland
      • Lublin, Poland
        • Recruiting
        • 1 Wojskowy Szpital Kliniczny Z Poliklinika SPZOZ W Lublinie
        • Contact:
          • Grzegorz Sobieszek, MD
  • Slovakia
      • Banská Bystrica, Slovakia, 974 01
        • Completed
        • SUSCCH Banska Bystrica
  • Switzerland
      • Bern, Switzerland, 3001
        • Recruiting
        • Lindenhofspital
        • Contact:
          • Samera Shakir, MD
      • Lausanne, Switzerland, 1005
        • Recruiting
        • Centre Hospitalier Universitaire Vaudois
        • Contact:
          • Stephane Fournier, MD
      • Olten, Switzerland, 4600
        • Recruiting
        • Solothurner Spitäler AG
        • Contact:
          • Yves Laurent Bayard, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with symptomatic coronary artery disease needing the treatment of de novo native coronary artery lesions

Description

Inclusion Criteria:

  • According to the IFU

Exclusion Criteria:

  • According to the IFU

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Target Lesion Failure (TLF)
Time Frame: 12 months
The primary endpoint will be Target Lesion Failure (TLF) at 12 months. TLF is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave MI, or clinically driven Target Lesion Revascularization (TLR).
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinically driven Target Lesion Revascularization (TLR)
Time Frame: 12 months
According to ARC-2 definition
12 months
Cardiovascular Death (CD)
Time Frame: 12 months
According to ARC-2 definition
12 months
Target Vessel MI
Time Frame: 12 months
According to ARC-2 definition
12 months
Definite scaffold thrombosis
Time Frame: 12 months
According to ARC-2 definition
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Biotronik AG

Investigators

  • Principal Investigator: Stefano Galli, MD, Centro Cardiologico Monzino

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 18, 2020

Primary Completion (Estimated)

May 1, 2030

Study Completion (Estimated)

May 1, 2030

Study Registration Dates

First Submitted

December 17, 2020

First Submitted That Met QC Criteria

December 17, 2020

First Posted (Actual)

December 22, 2020

Study Record Updates

Last Update Posted (Estimated)

November 21, 2025

Last Update Submitted That Met QC Criteria

November 18, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • C1908

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The primary outcome data will be shared after the publication of it.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on Magmaris

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe